Top

International Journal of Colorectal Disease

Published in:

01-12-2021 | Erectile Dysfunction | Review

Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis

Authors: Akshaya Srikanth Bhagavathula, Wubshet Tesfaye, Kota Vidyasagar

Published in: International Journal of Colorectal Disease | Issue 12/2021

Abstract

Background

Experimental evidence has revealed that phosphodiesterase five inhibitors (PDE5is) increase epithelial barrier function and suppress intestinal carcinogenesis. Few epidemiological studies have investigated the role of PDE5i in increasing the risk of colorectal cancer (CRC); however, these studies have proffered varying conclusions. We therefore aimed to perform a comprehensive review and meta-analysis to investigate whether PDE5i use is associated with the incidence of CRC.

Methods

Databases, namely, PubMed, Scopus, Embase, and Web of Science, were used for literature search. Observational studies (published until January 31, 2021) that assessed the association of PDE5i use with CRC incidence were considered. Pooled relative risk (RR) estimates and corresponding 95% confidence intervals (CIs) were calculated using the DerSimonian-Laird random-effects model.

Results

We identified four retrospective studies that involved 965,044 participants and 3,518 CRC cases detected during a mean follow-up of 12.7 years. Pooled results indicated a significantly reduced CRC risk among all PDE5i users (RR, 0.85; 95% CI, 0.76–0.95; P = 0.004, I² = 63%). Moreover, continuous use of PDE5i was associated with a significantly reduced risk of CRC (RR, 0.63; 95% CI, 0.59–0.68; P < 0.001, I² = 0.0%). However, the type of PDE5i exhibited no association with the risk of CRC (RR, 1.00; 95% CI, 0.98–1.02; I² = 84.7%).

Conclusion

Our findings suggest that continuous use of PDE5i was associated with a significantly reduced risk of CRC development. Future studies with a longitudinal design and adequate control of confounding factors are required to clarify whether a longer duration of PDE5i use alters the risk of CRC.

Peak TC, Richman A, Gur S, Yafi FA, Hellstrom WJG (2016) The role of PDE5 inhibitors and the NO/cGMP pathway in cancer. Sex Med Rev 4(1):74–84. https://doi.org/10.1016/j.sxmr.2015.10.004CrossRefPubMed

Bian K, Murad F. sGC-cGMP signaling: target for anticancer therapy. Adv Fetal Neonatal Physiol 2014;5–13

Aoun F, Slaoui A, Walid AHO et al (2018) Association between phosphodiesterase type 5 inhibitors and prostate cancer: a systematic review. Prog Urol 28(12):560–566. https://doi.org/10.1016/j.purol.2018.07.004CrossRefPubMed

Wu Y, Qu X, Wang Y et al (2019) Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis. Andrologia 51(2):e13198. https://doi.org/10.1111/and.13198CrossRefPubMed

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P (2017) Meta-analysis of the association between phosphodiesterase inhibitors (PDE5Is) and risk of melanoma. J Natl Cancer Inst 109(8). https://doi.org/10.1093/jnci/djx086

Loeb S, Folkvaljon Y, Lambe M et al (2015) Use of Phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 313(24):2449–2455. https://doi.org/10.1001/jama.2015.6604CrossRefPubMed

Lin S, Wang J, Wang L et al (2017) Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res 7(1):41–52PubMedPubMedCentral

Zhu B, Vemavarapu L, Thompson WJ, Strada SJ (2005) Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94(2):336–350. https://doi.org/10.1002/jcb.20286CrossRefPubMed

Mei X-L, Yang Y, Zhang Y-J et al (2015) Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. Am J Cancer Res 5(11):3311–3324PubMedPubMedCentral

10.

Islam BN, Sharman SK, Hou Y et al (2017) Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res (Phila) 10(7):377–388. https://doi.org/10.1158/1940-6207.Capr-17-0015CrossRef

11.

Sutton SS, Magagnoli J, Cummings TH, Hardin JW (2020) The association between phosphodiesterase-5 inhibitors and colorectal cancer in a national cohort of patients. Clin Transl Gastroenterol 11(6):e00173. https://doi.org/10.14309/ctg.0000000000000173CrossRefPubMedPubMedCentral

12.

Cea Soriano L, García Rodríguez LA (2020) No association between use of phosphodiesterase 5 inhibitors and colorectal cancer in men with erectile dysfunction. Pharmacoepidemiol Drug Saf 29(5):605–608. https://doi.org/10.1002/pds.5000CrossRefPubMed

13.

Cronin KA, Lake AJ, Scott S et al (2018) Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 124(13):2785–2800CrossRefPubMed

14.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535CrossRefPubMedPubMedCentral

15.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012

16.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605CrossRefPubMed

17.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Statistics Med 21:1539–1558CrossRef

18.

Huang W, Sundquist J, Sundquist K, Ji J (2019 Sep) Use of phosphodiesterase 5 inhibitors is associated with lower risk of colorectal cancer in men with benign colorectal neoplasms. Gastroenterology 157(3):672-681.e4. https://doi.org/10.1053/j.gastro.2019.05.012CrossRefPubMed

19.

Matthews A, Langan SM, Douglas IJ, Smeeth L, Bhaskaran K (2016) Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med 13(6):e1002037. https://doi.org/10.1371/journal.pmed.1002037CrossRefPubMedPubMedCentral

20.

Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA (2010) Colon tumor cell growth–inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res 3(10):1303–1313CrossRef

21.

Mei XL, Yang Y, Zhang YJ, Li Y, Zhao JM, Qiu JG, Zhang WJ, Jiang QW, Xue YQ, Zheng DW, Chen Y (2015) Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. Am J Cancer Res 5(11):3311PubMedPubMedCentral

22.

Cruz-Burgos M, Losada-Garcia A, Cruz-Hernández CD, Cortés-Ramírez SA, Camacho-Arroyo I, Gonzalez-Covarrubias V, Morales-Pacheco M, Trujillo-Bornios SI, Rodríguez-Dorantes M (2021) New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil. Front Oncol 11:208CrossRef

Title: Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis
Authors: Akshaya Srikanth Bhagavathula
Wubshet Tesfaye
Kota Vidyasagar
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Erectile Dysfunction
Phosphodiesterase-5 Inhibitor
Sildenafil
Colorectal Cancer
Colorectal Cancer
Published in: International Journal of Colorectal Disease / Issue 12/2021
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-021-04022-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2021

Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study

Readmission, healthcare consumption, and mortality in Clostridioides difficile infection hospitalizations: a nationwide cohort study

Robotic versus transanal total mesorectal excision in sexual, anorectal, and urinary function: a multicenter, prospective, observational study

Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer

Management, treatment and prognostic significance of lateral lymph node metastases in rectal cancer—a regional cohort study

Three distinct outcomes in patients with colorectal adenocarcinoma and lymphovascular invasion: the good, the bad, and the ugly